A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A treatment is being testedPhase 2
Running in: Fundeni Clinical Institute, București · Institutul Oncologic Cluj, Cluj-Napoca · Spitalul Clinic Municipal Filantropia Craiova, Craiova · Institutul Regional de Oncologie, Iași · Ovidius Clinical Hospital OCH, Ovidiu
See the official record ↗ NCT06588478
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
A treatment is being testedPhase 2
Running in: Centrul de Diagnostic si Tratament Oncologic Brasov ( Site 1802), Brașov · Spitalul Clinic Colțea ( Site 1805), București · Institutul Regional de Oncologie Iasi ( Site 1801), Iași · Ovidius Clinical Hospital ( Site 1804), Ovidiu
See the official record ↗ NCT04728893
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
A treatment is being testedPhase 3
Running in: Centrul de Diagnostic si Tratament Oncologic Brasov ( Site 2402), Brașov · Spitalul Clinic Colțea ( Site 2401), București · Institutul Oncologic Cluj ( Site 2404), Cluj-Napoca · Spital Judetean Sibiu ( Site 2405), Sibiu
See the official record ↗ NCT06717347
Global Trial in APG2575 for Patients With CLL/SLL
A treatment is being testedPhase 3
Running in: Ascentage Investigative Site, București · Ascentage Investigative Site, Cluj-Napoca · Ascentage Investigative Site, Timișoara
See the official record ↗ NCT06104566
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
A treatment is being testedPhase 3
Running in: Fundeni Clinical Institute /ID# 260296, București · Institutul Oncologic Prof Dr. Ion Chiricuta Cluj Napoca /ID# 259704, Cluj-Napoca · Institutul Regional de Oncologie /ID# 259697, Iași
See the official record ↗ NCT06191744
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A treatment is being testedPhase 3
Running in: Coltea Clinical Hospital, București · Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca, ClujNapoca · Institutul Regional de Oncologie Iasi, Iași
See the official record ↗ NCT06973187
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
A treatment is being testedPhase 2
Running in: Bucharest Oncology Institute "Prof.Dr.Al. Trestioreanu", București · The Oncology Institute "Prof. Dr. Ion Chiricuţă" I.O.C.H., Cluj-Napoca
See the official record ↗ NCT04920617
Study of SGR-1505 in Mature B-Cell Neoplasms
A treatment is being testedPhase 1
Running in: ARENSIA Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti, București · ARENSIA Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca, Cluj-Napoca
See the official record ↗ NCT05544019
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.
Observational study — you do not receive a new treatment
Running in: Cluj Napoca_Ion Chiricuta Oncology Institute, Cluj-Napoca
See the official record ↗ NCT03964480
Source: ClinicalTrials.gov, the public registry of the US National Library of Medicine. Read automatically, last on 31 Jul 2026.